Next, we investigated the effects of the SGLT2 inhibitor on T cell infiltration in vivo and confirmed that the SGLT2 inhibitor activated the STING/IRF3/IFN-β pathway in murine K7M2 tumor cells. This evidence concerns the gene SLC5A2 and neoplasm.